Opinion|Videos|January 12, 2026
Emerging Therapies in Schizophrenia
Panelists discuss how emerging therapies targeting new pathways may revolutionize schizophrenia management.
Advertisement
Episodes in this series
Panelists discuss how innovative treatments—including glutamatergic modulators, muscarinic agonists, and digital interventions—represent the next frontier of schizophrenia care.
Panelists discuss how these new agents aim to address cognitive and negative symptoms often resistant to traditional therapy, filling critical gaps in patient outcomes.
Panelists discuss how combining emerging pharmacologic innovations with technology-driven support could transform disease management over the next decade.
Advertisement
Related to this article
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
4
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
5